Regulus Therapeutics’ (NASDAQ:RGLS) RGLS4236 received FDA orphan drug designation for the treatment of autosomal dominant polycystic kidney disease (ADPKD). ADPKD is caused by mutations in the PKD1 or PKD2 genes, and is...
Tag - RGLS
Reporting on the healthcare industry’s corporate and clinical developments, executive moves and views from the Street.
Copyright © 2021 BioTuesday Publishing Corporation - Privacy Policy